Noticias y Actividades de Adagene

Adagene es una empresa que cotiza bajo el símbolo de cotización ADAG (CN).

Ver el organigrama con sus 18 ejecutivos principales

Biografías más buscadas en Adagene

• Peter Luo, Chief Executive Officer and Chairman of The Board
• Andy Cheung, Independent Director
• Zhu Li, Independent Director

Crear su alerta
para seguir los movimientos de los ejecutivos en Adagene.

Adagene tiene 2.428 competidores entre los que se incluyen Lonza (Suiza), Vertex Pharmaceuticals (Estados Unidos) y Eurofins (Luxemburgo).

Popular M&A news in Biotecnología

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado el 17 de julio de 2026).
• GSK ha Nuvalent adquirido (publicado el 17 de julio de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado el 15 de julio de 2026).

Otros contactos sugeridos en el sector Biotecnología

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer en Inceptive
• Jan Van de Winkel - President and Chief Executive Officer en Genmab
• Robert Gould - Board Member en Fulcrum Therapeutics

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Adagene

• News Releases – Adagene Inc.
• Adagene to Participate in Two Upcoming Investor Conferences – Adagene Inc.
• News Releases – Adagene Inc.
• Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types – Adagene Inc.
• Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board – Adagene Inc.
• News Releases – Adagene Inc.
• Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response – Adagene Inc.
• Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update – Adagene Inc.
• Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs – Adagene Inc.
• Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) – Adagene Inc.
• View more press releases Close

Redes sociales sobre Adagene

• Adagene en Wikipedia, Google News y Yahoo Finance
• Adagene en LinkedIn, Twitter y YouTube